April 2009
Volume 50, Issue 13
ARVO Annual Meeting Abstract  |   April 2009
A Phase I Clinical Trial to Study the Safety of a Sustained-Release Subconjunctival Cyclosporine (CsA) Implant for Ocular Graft-vs.-Host Disease (GVHD)
Author Affiliations & Notes
  • J. Austin Clayton
    Office of the Director, National Institute of Health, Bethesda, Maryland
  • C. Perry
    National Eye Institute, Bethesda, Maryland
  • M. Robinson
    Allergan, Irvine, California
  • Footnotes
    Commercial Relationships  J. Austin Clayton, US Government patent, P; C. Perry, None; M. Robinson, US Government patent, P.
  • Footnotes
    Support  Intramural Research Program at NEI/ NIH/ DHHS
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 4680. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Austin Clayton, C. Perry, M. Robinson; A Phase I Clinical Trial to Study the Safety of a Sustained-Release Subconjunctival Cyclosporine (CsA) Implant for Ocular Graft-vs.-Host Disease (GVHD). Invest. Ophthalmol. Vis. Sci. 2009;50(13):4680.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To investigate the safety and potential efficacy of a novel, subconjunctival CsA implant in active systemic GVHD with aqueous tear deficiency due to lacrimal gland involvement.

Methods: : Participants (pts) were randomized to 0.5 or 0.75 inch, 30% drug load, CsA impant. Standardized ocular surface disease (OSD) evaluation included tear production and stability, dye staining, meibomian gland function (MGD), Ocular Surface Disease Index and signal grading of "the main complaint" per eye. Safety and preliminary efficacy were assessed with pre-specified clinical success criteria for change from baseline or achievement of mild-moderate OSD.

Results: : 2 year follow-up (f/u) data are available for 4 pts: 2 White males, 1 Asian female, and 1 White Hispanic female. At baseline, 3/4 pts showed severe OSD OU (study eye, SE, and fellow eye, FE): corneal (K) staining ≥ 3, total conjunctival (conj) and K staining ≥ 12, maximum MGD score of 3, Schirmer (Sch) of 1 mm, and did not meet criteria for mild-moderate OSD. At 2 yrs, 4/4 SE’s and 1/4 FE’s met ≥ half of clinical success measures. 4/4 SE’s met success measures: improved K and conj staining (by ≥ 2), K staining ≤ 3, and nasal or temporal conj staining ≤ 3, while 2 FE’s showed improved K staining, K staining ≤ 3 and nasal and temporal conj staining ≤ 3. In 3/4 pts more success criteria were met in the SE than FE (SE, FE): Pt 1 (5, 0), Pt 2 (6, 2), Pt 3 (5, 2), Pt 4 (5, 5). 3/4 pts showed increased TBUT in the SE, vs.2/4 FE’s. 3/4 pts showed improved signal grading ≥ 2 points in the SE vs. 1 FE. 1 pt had improved OSDI score. F/u data for > 2 yrs is available for 2 pts who both showed additional reduction in K and conj staining to ≤ 1 and further increase in Schirmer in the SE, but not the FE, meeting the clinical success criterion in 1. No safety concerns were identified.

Conclusions: : There is preliminary evidence from this small pilot study for improvement in severe OSD with subconjunctival CsA implants in subjects with active, systemic GVHD. Further study is need to optimize CsA delivery, duration and dosage.

Clinical Trial: : www.clinicaltrials.gov NCT00102583

Keywords: inflammation • conjunctiva • lacrimal gland 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.